These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7918127)

  • 1. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
    Catimel G; Vermorken JB; Clavel M; de Mulder P; Judson I; Sessa C; Piccart M; Bruntsch U; Verweij J; Wanders J
    Ann Oncol; 1994 Jul; 5(6):543-7. PubMed ID: 7918127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent chemoradiation with low-dose and long-duration weekly infusion of gemcitabine in unresectable squamous cell carcinoma of head and neck (SCCHN).
    Ahmad F; Akram M; Khan M
    J Cancer Res Ther; 2024 Apr; 20(3):827-831. PubMed ID: 39023590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine in the treatment of advanced head and neck cancer.
    Raguse JD; Gath HJ; Bier J; Riess H; Oettle H
    Clin Oncol (R Coll Radiol); 2005 Sep; 17(6):425-9. PubMed ID: 16149285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.
    Samlowski WE; Gundacker H; Kuebler JP; Giguere JK; Mills GM; Schuller DE; Ensley JF
    Invest New Drugs; 2001; 19(4):311-5. PubMed ID: 11561690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.
    Sessa C; Aamdal S; Wolff I; Eppelbaum R; Smyth JF; Sulkes A; Ten Bokkel Huinink W; Vermorken J; Wanders J; Franklin H
    Ann Oncol; 1994 May; 5(5):471-2. PubMed ID: 8075055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
    Catimel G; Verweij J; Mattijssen V; Hanauske A; Piccart M; Wanders J; Franklin H; Le Bail N; Clavel M; Kaye SB
    Ann Oncol; 1994 Jul; 5(6):533-7. PubMed ID: 7918125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.
    Hitt R; Castellano D; Hidalgo M; García-Carbonero R; Peña M; Brandariz A; Millán JM; Alvarez Vincent JJ; Cortés-Funes H
    Ann Oncol; 1998 Dec; 9(12):1347-9. PubMed ID: 9932167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced breast cancer: a phase II trial with gemcitabine.
    Carmichael J; Possinger K; Phillip P; Beykirch M; Kerr H; Walling J; Harris AL
    J Clin Oncol; 1995 Nov; 13(11):2731-6. PubMed ID: 7595731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Cormier Y; Burkes R; Evans WK; Goss G; Klimo P; Feld R; Taylor M
    Semin Oncol; 1997 Jun; 24(3 Suppl 8):S8-27-S8-30. PubMed ID: 9207313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.
    Sandler AB; Kindler HL; Einhorn LH; Mitchell E; Masters G; Kraut M; Nicol S; Raghavan D
    Ann Oncol; 2000 Sep; 11(9):1161-4. PubMed ID: 11061612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
    Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
    Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck.
    Aguilar-Ponce J; Granados-García M; Villavicencio V; Poitevin-Chacón A; Green D; Dueñas-González A; Herrera-Gómez A; Luna-Ortiz K; Alvarado A; Martínez-Said H; Castillo-Henkel C; Segura-Pacheco B; De la Garza J
    Ann Oncol; 2004 Feb; 15(2):301-6. PubMed ID: 14760126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
    Stier S; Koll C; Neuhaus T; Fronhoffs S; Forkert R; Tuohimaa A; Vetter H; Ko Y
    Anticancer Drugs; 2005 Nov; 16(10):1115-21. PubMed ID: 16222154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
    Benasso M; Merlano M; Sanguineti G; Corvò R; Numico G; Ricci I; Pallestrini E; Santelli A; Vitale V; Marchetti G; Rosso R
    Am J Clin Oncol; 2001 Dec; 24(6):618-22. PubMed ID: 11801767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
    Aguilar-Ponce JL; Granados-García M; Cruz López JC; Maldonado-Magos F; Alvarez-Avitia MA; Arrieta O; González-Ramírez I; Lara-Cruz G; Martinez-Juárez I; Medina-Santillan R; Castillo-Hernández C; De la Garza-Salazar J
    Oral Oncol; 2013 Mar; 49(3):249-54. PubMed ID: 23043985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
    Tibaldi C; Ricci S; Russo F; Bernardini I; Galli L; Chioni A; Orlandini C; Grosso AM; Pegna AL; Fabbri A; Innocenti F; Ferrari K; Tognarini L; Conte PF; Falcone A;
    Lung Cancer; 2005 Apr; 48(1):121-7. PubMed ID: 15777979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
    Anderson H; Lund B; Bach F; Thatcher N; Walling J; Hansen HH
    J Clin Oncol; 1994 Sep; 12(9):1821-6. PubMed ID: 8083706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine: a phase II study in patients with advanced renal cancer.
    De Mulder PH; Weissbach L; Jakse G; Osieka R; Blatter J
    Cancer Chemother Pharmacol; 1996; 37(5):491-5. PubMed ID: 8599874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
    Fukuoka M; Takada M; Yokoyama A; Kurita Y; Niitani H
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-42-S7-46. PubMed ID: 9194479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.